Abstract
Monoclonal antibodies targeting the checkpoint inhibitors (CPIs), programmed cell death protein-1 or programmed cell death ligand-1, are changing the landscape of urothelial carcinoma therapeutics. Overall, clinical studies in metastatic or advanced urothelial cancer showed that CPIs provided a slight improvement in survival and a relevant advantage in safety, compared with chemotherapy. After reviewing published and ongoing trials, the authors discuss expected answers to unmet needs, with a special attention to the research of biological markers for patients with urothelial cancer eligible for treatment with CPIs in this article.
Original language | English |
---|---|
Pages (from-to) | 67-77 |
Number of pages | 11 |
Journal | Immunotherapy |
Volume | 13 |
Issue number | 1 |
DOIs | |
Publication status | Published - Jan 2021 |
Keywords
- atezolizumab
- checkpoint inhibitors
- durvalumab
- immunotherapy
- nivolumab
- PD-1
- PD-L1
- urothelial cancer
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology